Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Olipudase Alfa→

Olipudase Alfa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
927883-84-9
Molecular formula
C2900H4373N783O791S24
Molecular weight
63631.13 g/mol
Drug class
Recombinant human acid sphingomyelinaseenzyme replacement therapy biologic
Mechanism of action
Provides exogenous acid sphingomyelinase that hydrolyses sphingomyelin to ceramide and phosphorylcholine in lysosomes, reducing sphingomyelin accumulation in peripheral organs.
Indications / reported uses
  • Enzyme replacement therapy for non-central-nervous-system manifestations of acid sphingomyelinase deficiency (ASMD) in adults and paediatric patients; it does not treat CNS manifestations because the enzyme does not cross the blood-brain barrier

Sources: US DailyMed — XENPOZYME (olipudase alfa-rpcp) · EMA EPAR — Xenpozyme · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Recombinant human acid sphingomyelinase; enzyme replacement therapy biologic

Mechanism of action

Provides exogenous acid sphingomyelinase that hydrolyses sphingomyelin to ceramide and phosphorylcholine in lysosomes, reducing sphingomyelin accumulation in peripheral organs.

General use cases

  • Enzyme replacement therapy for non-central-nervous-system manifestations of acid sphingomyelinase deficiency (ASMD) in adults and paediatric patients; it does not treat CNS manifestations because the enzyme does not cross the blood-brain barrier

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Olipudase Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Olipudase Alfa Permitted Daily Exposure (PDE) report (the Olipudase Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Olipudase Alfa Occupational Exposure Limit (OEL) report (the Olipudase Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.